promitil + capecitabine

Promitil + capecitabine is a combination regimen consisting of **Promitil**, a pegylated liposomal formulation of a lipid-based prodrug of mitomycin C (MLP), and **capecitabine**, an oral fluoropyrimidine carbamate. Promitil is designed to enhance tumor-specific delivery and reduce systemic toxicity of mitomycin C by encapsulating a prodrug in liposomes, which is selectively activated in the tumor microenvironment. Capecitabine is an orally administered prodrug that is enzymatically converted to 5-fluorouracil (5-FU) in the tumor, inhibiting DNA synthesis. The combination is being evaluated primarily for the treatment of **advanced or refractory metastatic colorectal cancer**. Mechanistically, Promitil delivers mitomycin C to tumors where it crosslinks DNA, while capecitabine (as 5-FU) inhibits thymidylate synthase, disrupting DNA synthesis and repair. Both agents act synergistically as antineoplastic agents and radiosensitizers. This regimen is under clinical investigation and has not been approved for routine use. The combination has demonstrated disease stabilization and acceptable safety in phase 1 studies.

Brand names

Xeloda

Other names

mitomycin-c lipidic prodrug liposome + capecitabine